Education
About Us
Working with TipRanks
Follow Us
Tandem Diabetes Care (TNDM)
NASDAQ:TNDM
Top Page
Tandem Diabetes Care
(NASDAQ:TNDM)
Rating:50Neutral
Price Target:
$17.00
▼(-1.39%Downside)
Positive Factors
Financial Performance
Q1 revenue of $234.4M beat both CG and consensus estimates, driven by US and OUS supplies revenue.
Market Expansion
Expanding the indication into T2D could significantly expand TNDM's market potential.
Product Development
TNDM showcased advancements in its product pipeline, particularly the Mobi tubeless, which is in final packaging form and undergoing validation testing.
Negative Factors
Analyst Rating
The analyst recommendation maintains an 'UNDERPERFORM' rating with a price objective lower than the current market price.
Future Challenges
TNDM is working on payer negotiations for 2026, with a focus on growing coverage overall before driving more volume through pharmacy.
Tandem Diabetes Care (TNDM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.15B
Dividend YieldN/A
Average Volume (3M)1.34M
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue Growth27.65%
EPS Growth-28.22%
CountryUS
Employees2,650
SectorHealthcare
Sector Strength44
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.67
Shares Outstanding66,607,210
10 Day Avg. Volume1,297,739
30 Day Avg. Volume1,335,054
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)6.55
Price to Sales (P/S)0.00
P/FCF Ratio383.83
Enterprise Value/Market Cap2.73
Enterprise Value/Revenue0.80
Enterprise Value/Gross Profit6.10
Enterprise Value/Ebitda-7.41
Forecast
1Y Price Target
$37.79Price Target Upside119.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Tandem Diabetes Care Business Overview & Revenue Model
Company DescriptionTandem Diabetes Care (TNDM) is a medical device company focused on the design, development, and commercialization of products for people with insulin-dependent diabetes. The company operates primarily in the healthcare sector and specializes in offering innovative insulin pump solutions. Its flagship product, the t:slim X2 Insulin Pump, is known for its sleek design and advanced features, including continuous glucose monitoring (CGM) integration. Tandem aims to improve the lives of people with diabetes by providing user-friendly and technologically advanced insulin delivery systems.
How the Company Makes MoneyTandem Diabetes Care generates revenue primarily through the sale of its insulin pump systems and related accessories. The company's key revenue streams include direct sales of the t:slim X2 Insulin Pump, sales of disposable cartridges and infusion sets, and software upgrades for its devices. Additionally, Tandem offers customer support and training services, which are integral to its business model. Significant partnerships with continuous glucose monitoring companies, such as Dexcom, enhance its product offerings and appeal in the market. The company also benefits from insurance reimbursements and healthcare provider partnerships that facilitate access to its products for end-users.
Tandem Diabetes Care Earnings Call Summary
Earnings Call Date:Apr 30, 2025
(Q1-2025)
| % Change Since: 2.31%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
The earnings call reflects strong performance in Q1 with record sales and strategic expansions, particularly in the pharmacy channel and international markets. Significant product developments and operational improvements have positioned the company well, although some challenges remain in realizing immediate type 2 diabetes market impacts and navigating market transitions.Q1-2025 Updates
Positive Updates
Record First-Quarter Sales
Achieved record first-quarter sales of $234 million, marking a 22% year-over-year growth. This includes $151 million in the U.S. (15% increase) and $84 million internationally (35% increase).
Successful Product Launch and FDA Clearance
FDA cleared Control-IQ+ for type 2 diabetes, and the New England Journal of Medicine published results highlighting its benefits. This more than doubles the addressable market.
Strong Customer Retention and New Starts
Double-digit increase in new pump starts, with significant conversions from multiple daily injections. Renewal rates remain high with a healthy product mix.
Gross Margin and EBITDA Improvement
Achieved a 51% gross margin and improved adjusted EBITDA margin by 5 percentage points year-over-year, driven by pump cost efficiencies and favorable pricing.
Expansion in Pharmacy Channel
Approximately 30% of U.S. lives are covered under the pharmacy benefit, with improvement in pricing and reduced out-of-pocket costs for customers.
International Growth and Direct Sales Plans
Strong international sales momentum with plans to begin direct sales in select countries by 2026, enhancing market presence and financial performance.
Negative Updates
Limited Type 2 Commercial Impact in 2025
Despite FDA clearance, only modest contribution from type 2 diabetes sales is expected in 2025 due to reimbursement and Medicare access challenges.
Potential Headwinds from Market Transitions
Anticipate $15 million to $20 million headwinds in the back half of 2025 due to transitioning to direct sales in select international markets.
Sales Force Realignment Disruptions
Although managed well, the sales force expansion and realignment caused some temporary disruptions, with full productivity expected by Q4.
Company Guidance
During the Tandem Diabetes Care First Quarter 2025 Earnings Conference Call, the company reported robust performance metrics, including a 22% year-over-year growth in worldwide sales, reaching a record $234 million. The U.S. saw a 15% increase in sales, driven by healthy pump shipments, strong supply sales, and improved average selling prices. Internationally, sales surged by 35% year-over-year, totaling $84 million, marking the highest quarterly sales to date. The company also reported a significant improvement in adjusted EBITDA margins by five percentage points year-over-year. Tandem reiterated its commitment to delivering double-digit growth and improved profitability, maintaining its 2025 guidance for sales to range between $997 million and just over $1 billion and aiming for a 54% gross margin. Additionally, Tandem highlighted FDA clearance of Control-IQ+ for type 2 diabetes, which has expanded their addressable market, and discussed strategic initiatives such as pharmacy channel expansion and international sales operations.Tandem Diabetes Care Financial Statement Overview
Summary
Tandem Diabetes Care shows strong revenue growth but faces significant profitability challenges. High leverage and negative cash flow trends present financial risks, with a negative net profit margin and high debt-to-equity ratio.Income Statement
Tandem Diabetes Care's income statement shows a mixed performance. The TTM (Trailing-Twelve-Months) gross profit margin is healthy at 46.6%, indicating effective cost management. However, the company is struggling with profitability, as evidenced by negative net profit margin (-16.7%) and EBIT margin (-9.4%). Revenue growth is strong with a 17.2% increase from the previous year, but consistent operating losses are a concern.40
Negative
Balance Sheet
The balance sheet reflects financial vulnerability with a high debt-to-equity ratio of 3.18, suggesting significant leverage. The equity ratio of 16.8% indicates heavy reliance on debt for financing. Return on equity is negative at -118.4%, reflecting poor returns for shareholders. The company maintains a reasonable cash position, but overall financial stability is weak.35
Negative
Cash Flow
Cash flow analysis reveals challenges, with negative free cash flow in the TTM period. The operating cash flow to net income ratio is 0.08, showing limited cash generation from operations. The free cash flow to net income ratio is negative, indicating cash outflows exceeding net income. Although there is a positive free cash flow growth from 2023 to 2024, the overall cash flow health is concerning.45
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.10B | 940.20M | 747.72M | 801.22M | 702.80M | 498.83M |
| Gross Profit | 513.31M | 489.57M | 367.69M | 412.99M | 376.21M | 260.52M |
| EBITDA | -150.68M | -99.13M | -194.66M | -72.31M | 36.50M | -13.03M |
| Net Income | -183.87M | -96.03M | -222.61M | -94.59M | 15.57M | -34.38M |
Balance Sheet | ||||||
| Total Assets | 922.14M | 967.66M | 952.66M | 1.05B | 905.14M | 716.41M |
| Cash, Cash Equivalents and Short-Term Investments | 368.63M | 438.33M | 467.91M | 616.90M | 623.81M | 484.94M |
| Total Debt | 493.20M | 473.56M | 415.67M | 419.88M | 314.67M | 228.32M |
| Total Liabilities | 766.85M | 704.56M | 639.03M | 612.84M | 472.02M | 350.11M |
| Stockholders Equity | 155.29M | 263.10M | 313.63M | 439.95M | 433.11M | 366.31M |
Cash Flow | ||||||
| Free Cash Flow | -50.20M | 4.99M | -83.41M | 7.51M | 87.85M | -7.63M |
| Operating Cash Flow | 13.94M | 24.23M | -31.81M | 50.46M | 111.36M | 24.67M |
| Investing Cash Flow | -9.24M | -23.48M | -85.74M | 33.17M | -186.88M | -296.06M |
| Financing Cash Flow | -9.91M | 8.37M | 4.11M | 16.88M | 51.93M | 314.44M |
Tandem Diabetes Care Technical Analysis
Negative
17.24
Price Trends
20.40
Negative
21.45
Negative
28.54
Negative
Market Momentum
-0.77
Positive
28.76
Positive
15.69
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNDM, the sentiment is Negative. The current price of 17.24 is below the 20-day moving average (MA) of 19.95, below the 50-day MA of 20.40, and below the 200-day MA of 28.54, indicating a bearish trend. The MACD of -0.77 indicates Positive momentum. The RSI at 28.76 is Positive, neither overbought nor oversold. The STOCH value of 15.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TNDM.
Tandem Diabetes Care Risk Analysis
Tandem Diabetes Care disclosed 62 risk factors in its most recent earnings report. Tandem Diabetes Care reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tandem Diabetes Care Peers Comparison
Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $1.94B | 30.91 | 19.36% | ― | 34.43% | 31.90% | |
78 Outperform | $32.77B | 62.74 | 23.72% | ― | 9.11% | -17.87% | |
76 Outperform | $21.11B | 53.99 | 37.92% | ― | 23.49% | 71.25% | |
65 Neutral | $1.27B | 16.57 | 5.12% | ― | -0.05% | ― | |
62 Neutral | $2.49B | 30.62 | -19.69% | ― | 7.97% | -592.40% | |
50 Neutral | $1.15B | ― | -92.31% | ― | 27.65% | -28.22% | |
46 Neutral | C$192.85M | -4.25 | -8.56% | 2.91% | 13.52% | -1.74% |
* Healthcare Sector Average
Performance Comparison
TNDM
Tandem Diabetes Care
17.08
-22.74
-57.11%
DXCM
Dexcom
83.58
-27.33
-24.64%
PODD
Insulet
301.62
104.90
53.32%
UFPT
Ufp Technologies
245.87
-44.37
-15.29%
LIVN
LivaNova
46.08
-6.71
-12.71%
AHCO
AdaptHealth
9.37
-0.33
-3.40%
Tandem Diabetes Care Corporate Events
Executive/Board ChangesLegal ProceedingsShareholder Meetings
Tandem Diabetes Care Settles Patent Disputes with Roche
Neutral
May 23, 2025
On May 21, 2025, Tandem Diabetes Care, Inc. and Roche entities settled patent disputes related to insulin delivery systems, agreeing to terminate pending actions and granting each other non-exclusive licenses for ten years. Additionally, Tandem held its virtual Annual Meeting of Stockholders on the same day, where eight directors were elected, executive compensation was approved, and Ernst & Young LLP was ratified as the independent registered public accounting firm for 2025.
The most recent analyst rating on (TNDM) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Tandem Diabetes Care stock, see the TNDM Stock Forecast page.
Product-Related AnnouncementsBusiness Operations and Strategy
Tandem Diabetes Care Gains CE Mark Approval
Positive
May 20, 2025
On May 16, 2025, Tandem Diabetes Care received CE mark approval for its Tandem Mobi insulin delivery system with Control-IQ+ technology. The company plans to pursue further regulatory and pre-commercial activities in the EU, aiming for commercial launches by the end of 2025.
The most recent analyst rating on (TNDM) stock is a Hold with a $46.00 price target. To see the full list of analyst forecasts on Tandem Diabetes Care stock, see the TNDM Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.